Literature DB >> 22002228

Assessment of the molecular expression and structure of gangliosides in brain metastasis of lung adenocarcinoma by an advanced approach based on fully automated chip-nanoelectrospray mass spectrometry.

Alina D Zamfir1, Alina Serb, Željka Vukeli, Corina Flangea, Catalin Schiopu, Dragana Fabris, Svjetlana Kalanj-Bognar, Florina Capitan, Eugen Sisu.   

Abstract

Gangliosides (GGs), sialic acid-containing glycosphingolipids, are known to be involved in the invasive/metastatic behavior of brain tumor cells. Development of modern methods for determination of the variations in GG expression and structure during neoplastic cell transformation is a priority in the field of biomedical analysis. In this context, we report here on the first optimization and application of chip-based nanoelectrospray (NanoMate robot) mass spectrometry (MS) for the investigation of gangliosides in a secondary brain tumor. In our work a native GG mixture extracted and purified from brain metastasis of lung adenocarcinoma was screened by NanoMate robot coupled to a quadrupole time-of-flight MS. A native GG mixture from an age-matched healthy brain tissue, sampled and analyzed under identical conditions, served as a control. Comparative MS analysis demonstrated an evident dissimilarity in GG expression in the two tissue types. Brain metastasis is characterized by many species having a reduced N-acetylneuraminic acid (Neu5Ac) content, however, modified by fucosylation or O-acetylation such as Fuc-GM4, Fuc-GM3, di-O-Ac-GM1, O-Ac-GM3. In contrast, healthy brain tissue is dominated by longer structures exhibiting from mono- to hexasialylated sugar chains. Also, significant differences in ceramide composition were discovered. By tandem MS using collision-induced dissociation at low energies, brain metastasis-associated GD3 (d18:1/18:0) species as well as an uncommon Fuc-GM1 (d18:1/18:0) detected in the normal brain tissue could be structurally characterized. The novel protocol was able to provide a reliable compositional and structural characterization with high analysis pace and at a sensitivity situated in the fmol range. © American Society for Mass Spectrometry, 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002228     DOI: 10.1007/s13361-011-0250-5

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  61 in total

1.  GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside.

Authors:  H Hamasaki; M Aoyagi; T Kasama; S Handa; K Hirakawa; T Taki
Journal:  Biochim Biophys Acta       Date:  1999-01-29

2.  Anencephaly: structural characterization of gangliosides in defined brain regions.

Authors:  Z Vukelić; W Metelmann; J Müthing; M Kos; J Peter-Katalinić
Journal:  Biol Chem       Date:  2001-02       Impact factor: 3.915

Review 3.  Lipid characteristics in metastatic cells.

Authors:  S Ruggieri; G Mugnai; A Mannini; L Calorini; A Fallani; E Barletta; G Mannori; O Cecconi
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

4.  High-throughput analysis of gangliosides in defined regions of fetal brain by fully automated chip-based nanoelectrospray ionization multi-stage mass spectrometry.

Authors:  Alina Serb; Catalin Schiopu; Corina Flangea; Zeljka Vukelić; Eugen Sisu; Leon Zagrean; Alina D Zamfir
Journal:  Eur J Mass Spectrom (Chichester)       Date:  2009       Impact factor: 1.067

Review 5.  The sialyl-alpha2,6-lactosaminyl-structure: biosynthesis and functional role.

Authors:  F Dall'Olio
Journal:  Glycoconj J       Date:  2000-10       Impact factor: 2.916

6.  Suppression of lung metastasis of mouse Lewis lung cancer P29 with transfection of the ganglioside GM2/GD2 synthase gene.

Authors:  Ho-Hsiang Chen; Satoshi Fukumoto; Keiko Furukawa; Akimasa Nakao; Seiji Akiyama; Takeshi Urano; Koichi Furukawa
Journal:  Int J Cancer       Date:  2003-01-10       Impact factor: 7.396

7.  Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Authors:  Minesh P Mehta; Patrick Rodrigus; C H J Terhaard; Aroor Rao; John Suh; Wilson Roa; Luis Souhami; Andrea Bezjak; Mark Leibenhaut; Ritsuko Komaki; Christopher Schultz; Robert Timmerman; Walter Curran; Jennifer Smith; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

8.  Membrane raft disruption promotes axonogenesis in n2a neuroblastoma cells.

Authors:  Kimberly A Petro; Cara-Lynne Schengrund
Journal:  Neurochem Res       Date:  2008-02-29       Impact factor: 3.996

Review 9.  The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Steven N Kalkanis; Douglas Kondziolka; Laurie E Gaspar; Stuart H Burri; Anthony L Asher; Charles S Cobbs; Mario Ammirati; Paula D Robinson; David W Andrews; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Mark E Linskey
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

Review 10.  The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Mario Ammirati; Charles S Cobbs; Mark E Linskey; Nina A Paleologos; Timothy C Ryken; Stuart H Burri; Anthony L Asher; Jay S Loeffler; Paula D Robinson; David W Andrews; Laurie E Gaspar; Douglas Kondziolka; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Roy A Patchell; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-03       Impact factor: 4.130

View more
  9 in total

1.  Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus.

Authors:  Ligia Petrica; Adrian Vlad; Gheorghe Gluhovschi; Alina Zamfir; Cristina Popescu; Florica Gadalean; Victor Dumitrascu; Daliborca Vlad; Roxana Popescu; Silvia Velciov; Cristina Gluhovschi; Flaviu Bob; Oana Milas; Sorin Ursoniu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Characterization and Modeling of the Collision Induced Dissociation Patterns of Deprotonated Glycosphingolipids: Cleavage of the Glycosidic Bond.

Authors:  Marko Rožman
Journal:  J Am Soc Mass Spectrom       Date:  2015-08-22       Impact factor: 3.109

3.  Structural documentation of glycan epitopes: sequential mass spectrometry and spectral matching.

Authors:  David J Ashline; Andrew J S Hanneman; Hailong Zhang; Vernon N Reinhold
Journal:  J Am Soc Mass Spectrom       Date:  2014-01-03       Impact factor: 3.109

4.  Early stage fetal neocortex exhibits a complex ganglioside profile as revealed by high resolution tandem mass spectrometry.

Authors:  Roxana M Ghiulai; Mirela Sarbu; Željka Vukelić; Constantin Ilie; Alina D Zamfir
Journal:  Glycoconj J       Date:  2014-04       Impact factor: 2.916

5.  Characterization of Glycosphingolipids and Their Diverse Lipid Forms through Two-Stage Matching of LC-MS/MS Spectra.

Authors:  Laura S Bailey; Fanran Huang; Tianqi Gao; Jinying Zhao; Kari B Basso; Zhongwu Guo
Journal:  Anal Chem       Date:  2021-02-03       Impact factor: 6.986

6.  Lipidomics of glycosphingolipids.

Authors:  Hany Farwanah; Thomas Kolter
Journal:  Metabolites       Date:  2012-02-02

Review 7.  Recent advances in the mass spectrometric analysis of glycosphingolipidome - A review.

Authors:  Rodell C Barrientos; Qibin Zhang
Journal:  Anal Chim Acta       Date:  2020-05-24       Impact factor: 6.911

8.  Epigenetic hypomethylation and upregulation of GD3s in triple negative breast cancer.

Authors:  Wan Li; Xiangjin Zheng; Liwen Ren; Weiqi Fu; Jinyi Liu; Jun Xv; Shiwei Liu; Jinhua Wang; Guanhua Du
Journal:  Ann Transl Med       Date:  2019-12

Review 9.  Gangliosides as Biomarkers of Human Brain Diseases: Trends in Discovery and Characterization by High-Performance Mass Spectrometry.

Authors:  Mirela Sarbu; Raluca Ica; Alina D Zamfir
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.